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Therapeutic strategies directed against defined molecular subsets of non-small cell lung cancer (NSCLC) has underscored the transformative potential of biomarker directed drug 
development in  oncogene-driven solid tumors.1,2 Riding on the success of targeting epidermal 
growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrange-
ments, small molecule inhibitors of the phosphatidyl-inositol 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin (mTOR) pathway have engendered much excitement due to its 
critical role as a central signaling axis downstream of several receptor tyrosine kinases impli-
cated in NSCLC (e.g., EGFR and MET).3 Although published data of novel agents targeting 
the PI3K/AKT/mTOR pathway in NSCLC have only demonstrated modest clinical activity to 
date (Table 1), the majority of studies have been conducted in unselected patient populations.
In this issue of the journal, Vansteenkiste et al11 report the final efficacy results from a 
phase II trial of buparlisib, a pan-class I PI3K inhibitor in selected “PI3K-activated” NSCLC 
patients. In a commendable effort, 1242 patient samples underwent molecular prescreening 
for PIK3CA mutations, PTEN mutations, or PTEN loss by immunohistochemistry, iden-
tifying 63 subjects (13.5%) that were enrolled into two cohorts (squamous and nonsqua-
mous). In terms of efficacy analysis, this trial used a conservative futility  criterion—defined 
as 12-week progression-free survival rate less than 50%—that was unfortunately met in 
the first stage, terminating the trial early. Despite being a negative study from an efficacy 
standpoint, this trial has provided unique insights into the current challenges with targeted 
therapies directed against genetic alterations.
Underpinning the success of contemporary trials evaluating targeted therapeutics 
are patient enrichment strategies using high-precision predictive biomarkers. Are PTEN 
and PIK3CA alterations sufficiently specific to select for tumors most likely to respond to 
PI3K inhibitors? Preclinical data certainly support this hypothesis, where PIK3CA-mutant 
transgenic lung cancer mouse models clearly respond to PI3K/mTOR inhibitors,12 and 
conditional ablation of PIK3CA or PIK3CB (through which PTEN signals) in cell-based 
models result in a significant reduction in cell growth.13,14 Yet, despite selecting for the 
relevant alterations in this trial, tumor responses were disappointingly low at 3% in both 
nonsquamous and squamous cell carcinoma, and there was no difference in progression-
free survival regardless of whether patients’ tumors were PIK3CA mutant or wild type. 
Furthermore, a subgroup of 23 patients with sufficient archival tissue subjected to broader 
sequencing of 600 genes failed to yield any notable coalterations that may have limited 
the efficacy of PI3K inhibitors. Similarly, responders were not differentiated by a specific 
mutational profile, with one patient harboring PTEN loss in the squamous group while 
another patient in the nonsquamous group had a PIK3CA and a KRAS mutation. Thus, 
somatic alterations alone cannot explain response or resistance to buparlisib.
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One drawback of this study is that the majority of patients 
(62 of 64) did not undergo a fresh tumor biopsy before enroll-
ment, potentially limiting the clinical relevance of the tissue 
evaluated and imposing restrictions on the repertoire of feasible 
assays. Comprehensive integrative “omic” efforts employing 
whole genome and RNA sequencing have been reported as via-
ble strategies for biomarker discovery15 and highlight the value 
of contemporaneous high-quality tumor biopsies in oncology 
drug development. Given the dynamic nature of tumor muta-
tional profiles, an expanding area of research has been the use 
of noninvasive methods for molecular testing.16 In this trial, 
exploratory analysis of plasma-based circulating tumor DNA 
was performed in 38 patients where PIK3CA mutations were 
established in tumor, revealing a concordance rate of 55.3%. A 
higher concordance was observed with circulating tumor DNA 
and metastatic sites (as opposed to primary tumors), raising the 
possibility that PIK3CA mutations tend to occur late. In support 
of this hypothesis, a recent analysis of 2694 The Cancer Genome 
Atlas tumors across nine cancer types, performed to infer clonal-
ity and the timing of genomic alterations, found that a significant 
proportion of PIK3CA or PTEN mutations (>10–20%) were 
subclonal events.17 These findings are consistent with the limited 
efficacy of buparlisib observed in BASALT-1, where the maxi-
mal duration of response in two patients was 73 and 85 days.
So, what next after yet another failed PI3K inhibitor in 
the clinic? Despite the substantial effort in screening for PTEN 
and PIK3CA alterations in BASALT-1, the inadequate patient 
selection strategy exemplifies the limitations of single gene 
stratification approaches for certain therapeutic targets and/or 
cancers. It is plausible that refining patient selection through 
integration of genomic, transcriptomic, and/or phosphopro-
tein data may further enrich for responders, with increased 
emphasis on biospecimens procured at clinically relevant time 
points.18 In addition, ascertaining the context and hierarchy of 
coexisting alterations can provide insights to therapeutic vul-
nerability, and perhaps form the basis for novel combinato-
rial approaches. Finally, pharmacology matters, and we have 
to entertain the possibility that buparlisib may not be an ideal 
PI3K inhibitor. Of note, buparlisib has been shown to be an 
inhibitor of tubulin polymerization.19 This off-target effect may 
contribute to toxicities and impede the intended pathway mod-
ulation and efficacy. It is anticipated that the newer generation 
selective PI3K inhibitors that target specific catalytic subunits 
will have more favorable toxicity profiles20 while achieving 
potent pathway inhibition—which may be necessary to elicit 
responses in specific PI3K pathway alterations (e.g., PTEN 
versus PIK3CA) in the appropriate tumor context.
REFERENCES
 1. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clini-
cal trials in oncology: a paradigm shift in drug development. Cancer J 
2009;15:406–420.
 2. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-
cell lung cancer. J Clin Oncol 2013;31:1097–1104.
 3. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent effi-
cacy of single and combined PI3K- and MAPK-pathway inhibition in 
cancer. Proc Natl Acad Sci U S A 2009;106:18351–18356.
 4. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus 
(RAD001) in patients with advanced NSCLC previously treated with che-
motherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 
2009;20:1674–1681.
 5. Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, 
and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I 
PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 
2014;20:233–245.
 6. Gandhi L, Bahleda R, Tolaney SM, et al. Phase I study of neratinib 
in combination with temsirolimus in patients with human epidermal 
growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 
2014;32:68–75.
 7. Jänne PA, Cohen RB, Laird AD, et al. Phase I safety and pharmacokinetic 
study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination 
with erlotinib in patients with advanced solid tumors. J Thorac Oncol 
2014;9:316–323.
 8. Levy B, Spira A, Becker D, et al. A randomized, phase 2 trial of Docetaxel 
with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase 
inhibitor, in patients with relapsed or metastatic non-small-cell lung can-
cer. J Thorac Oncol 2014;9:1031–1035.
 9. Soria JC, LoRusso P, Bahleda R, et al. Phase I dose-escalation study 
of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in 
TABLE 1.  Published Trials Targeting PI3K/AKT/mTOR Pathway in NSCLC
Author Year Phase Agent Target n Biomarker Response  
Rate (%)
Soria et al4 2009 Phase II Everolimus mTOR 85 Unselected 4.7
Shapiro et al5 2014 Phase I XL147 PI3K 24 Unselected 4
Gandhi et al6 2014 Phase I Neratinib + 
temsirolimus
mTOR 11 Unselected 18.2*
Jänne et al7 2014 Phase I XL765 + erlotinib PI3K 37 Unselected 0
Levy et al8 2014 Randomized phase II PX-866 + docetaxel PI3K 48 Unselected 6
Soria et al9 2015 Phase I XL147 + erlotinib PI3K 35 Unselected 3.7
Lopez-Chavez et al10 2015 Umbrella MK2206 AKT 4 Selected for PI3K/
AKT/ 
mTOR alterations
0
Lara Jr et al 2015 Phase II MK2206 + erlotinib AKT 80  
(Stratum 1: 45; 
Stratum 2: 35)
Stratum 1: EGFR 
mutant; Stratum 2: 
EGFR wild type
Stratum 1: 9%;  
Stratum 2: 3%
*Responses seen in two patients with HER2-mutant NSCLC.
AKT, XXX; mTOR, XXX; NSCLC, non–small-cell lung cancer; PI3K, phosphotidyl 3-kinase.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1239Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 9, September 2015 High-Precision Genomic Biomarkers
combination with erlotinib in patients with solid tumors. Oncologist 
2015;20:245–246.
 10. Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and 
targeted therapy for advanced thoracic malignancies: a biomarker-
derived, multiarm, multihistology phase II basket trial. J Clin Oncol 
2015;33:1000–1007.
 11. Vansteenkiste JF, Canon J-L, De Braud F, et al. Safety and efficacy of 
buparlisib (BKM120) in patients with PI3K pathway-activated non small 
cell lung cancer (NSCLC): results from the phase II BASALT-1 study. 
J Thorac Oncol 2015;10:1319–1327.
 12. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK 
inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung 
cancers. Nat Med 2008;14:1351–1356.
 13. Zhao JJ, Cheng H, Jia S, et al. The p110alpha isoform of PI3K is essential 
for proper growth factor signaling and oncogenic transformation. Proc 
Natl Acad Sci U S A 2006;103:16296–16300.
 14. Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend 
on PIK3CB. Proc Natl Acad Sci U S A 2008;105:13057–13062.
 15. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology 
through integrative high-throughput sequencing: a pilot study. Sci Transl 
Med 2011;3:111ra121.
 16. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating 
tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650–661.
 17. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton 
C. Clonal status of actionable driver events and the timing of mutational 
processes in cancer evolution. Sci Transl Med 2015;7:283ra54.
 18. Tan DS, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: 
understanding the mechanisms through the use of integrative genomics 
and functional RNA interference. Eur J Cancer 2010;46:2166–2177.
 19. Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization 
of the mechanism of action of the pan class I PI3K inhibitor NVP-
BKM120 across a broad range of concentrations. Mol Cancer Ther 
2012;11:1747–1757.
 20. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The 
emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol 
Cell Biol 2010;11:329–341.
